Tesi R J, Henry M L, Elkhammas E A, Davies E A, Ferguson R M
Department of Surgery, Tulane University Medical Center, New Orleans, Louisiana 70112-2699.
Transplantation. 1994 Aug 27;58(4):424-30. doi: 10.1097/00007890-199408270-00006.
The recipients of combined kidney-pancreas transplants (SPK) are unique because they routinely receive two allografts from the same donor. In a previous study, we found that the long-term graft survival of the two allografts was different, with better graft survival seen in the pancreas allograft. In an attempt to understand the reason for the different graft survival in the recipients of organs from the same donor, we have reviewed the incidence and timing of rejection episodes in 160 consecutive technically successful whole-organ bladder-drained SPK performed at a single institution using a uniform immunosuppressive regimen. Rejection episodes were common. A total of 53% of the recipients had at least one episode of rejection in one of the organs. Multiple rejection episodes requiring hospitalization occurred in 23% of the recipients. The kidney allograft had more frequent rejection episodes than the pancreas allograft: 78 patients had 130 renal rejection episodes while only 50 patients had 65 episodes of pancreas rejection. No rejection episodes occurred in 111 pancreas and 82 kidney grafts (P = 0.0014). Multiple rejection episodes were three times as common in the kidney grafts (20%) than in the pancreas grafts (6%; P = 0.0001). The timing of the first rejection episode was also different. The median time to the first kidney rejection episode was 29 days compared with 39 days to the first pancreas rejection episode (P = 0.0191). Graft survival in the organs was equal when stratified by the number of rejection episodes (none, one, > one) per organ (P = 0.9378). These data suggest that the worse long-term kidney graft survival seen in SPK recipients is due to the greater risk of rejection (relative risk: 2.04; [95% conf. interval: 1.29-3.23]) and a greater frequency of rejection episodes of rejection episodes in the kidney (0.81/patient) compared with the pancreas (0.41/patient). The implications for patient management and the possible reasons for the different rates of rejection are discussed.
胰肾联合移植(SPK)受者具有独特性,因为他们通常会接受来自同一供体的两个同种异体移植物。在之前的一项研究中,我们发现这两个同种异体移植物的长期移植物存活率有所不同,胰腺同种异体移植物的移植物存活率更高。为了弄清楚来自同一供体的器官受者中移植物存活率不同的原因,我们回顾了在单一机构采用统一免疫抑制方案进行的160例连续技术成功的全器官膀胱引流式SPK中排斥反应发作的发生率和时间。排斥反应发作很常见。共有53%的受者在其中一个器官中至少发生过一次排斥反应。23%的受者发生了需要住院治疗的多次排斥反应发作。肾同种异体移植物的排斥反应发作比胰腺同种异体移植物更频繁:78例患者发生了130次肾排斥反应发作,而只有50例患者发生了65次胰腺排斥反应发作。111个胰腺移植物和82个肾移植物未发生排斥反应发作(P = 0.0014)。多次排斥反应发作在肾移植物中(20%)的发生率是胰腺移植物中(6%)的三倍(P = 0.0001)。首次排斥反应发作的时间也有所不同。首次肾排斥反应发作的中位时间为29天,而首次胰腺排斥反应发作的中位时间为39天(P = 0.0191)。根据每个器官排斥反应发作的次数(无、一次、>一次)进行分层时,各器官的移植物存活率相同(P = 0.9378)。这些数据表明,SPK受者中肾移植物长期存活率较差是由于排斥风险更高(相对风险:2.04;[95%置信区间:1.29 - 3.23]),且肾排斥反应发作的频率(0.81/患者)高于胰腺(0.41/患者)。文中讨论了对患者管理的影响以及排斥反应发生率不同的可能原因。